On Friday, Shares of American Capital Ltd. (NASDAQ:ACAS), gained 0.78% to $14.23.
Atossa Genetics, declared that it has signed manufacturing and quality agreements with AAIPharma Services Corp. / Cambridge Major Laboratories, Inc. (AAI/CML) for the manufacturing of a clinical supply for 4-Hydroxytamoxifen, the active pharmaceutical ingredient (API) in Atossa’s leading drug candidate, Afimoxifene Gel. In May 2015, Atossa attained from Besins Healthcare the exclusive rights to Afimoxifene Gel for the potential treatment of hyperplasia of the breast.
Dr. Steven Quay, Chairman, CEO & President of Atossa Genetics, said, “Securing a manufacturing source for the API marks important progress of our clinical program. With the manufacturing and quality agreements in place, AAI/CML will now start its work to manufacture a clinical supply of the API. We expect that the initial production of the API will be accomplished by the end of 2015 and once combined with the proprietary gel to form the clinical drug product we can then start clinical studies in 2016.”
“We appreciate this opportunity and look forward to working on Atossa’s leading drug candidate. This relationship is an excellent example of our dedication to delivering reliable, flexible and high quality service from our Germantown, WI facility. We look forward to supporting Atossa for its future clinical and commercial success,” stated Dr. Stephan Kutzer, CEO, President and Chairman of AAIPharma Services Corp. / Cambridge Major Laboratories, Inc.
American Capital, Ltd. is a private equity and venture capital firm specializing in administration and employee buyouts, subordinated debt, leveraged finance, mezzanine, acquisition, recapitalization, middle market, early venture, mature, industry consolidation, and growth capital investments.
Shares of IMS Health Holdings Inc (NYSE:IMS), declined -0.06% to $30.96, during its last trading session.
IMS Health Holdings, declared results for the quarter ended June 30, 2015.
Second-Quarter 2015 Operating Results
Revenue for the second quarter of $742 million was up 24.6 percent on a constant currency basis and 12.0 percent on a stated basis, contrast with the second quarter of 2014. Early in the second quarter, the company closed the acquisition of Cegedim’s CRM and Planned Data businesses. Not taking into account the impact of the Cegedim Acquisition, revenue was up 5.2 percent on a constant currency basis and down 4.6 percent on a stated basis, with the difference entirely due to the year-over-year strengthening of the U.S. dollar as compared to key currencies in which the company transacts business.
The company’s strong revenue growth in the second quarter comprised of a 45.6 percent enhance in technology services revenue on a constant currency basis, up 33.3 percent on a stated basis, as compared to the same period last year. Information offerings revenue was up 9.4 percent on a constant currency basis and down 3.2 percent stated. Emerging markets revenue raised 29.4 percent in the second quarter on a constant currency basis and 8.8 percent on a stated basis. Developed markets revenue grew 23.5 percent on a constant currency basis and 12.7 percent stated.
IMS Health Holdings, Inc. provides information and technology services to healthcare industry worldwide. Its principal products comprise national information offerings that provide performance metrics related to the sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity through multiple channels; and sub-national offerings, which offer information related to the measurement of sales at the regional, zip code, and individual prescriber level.
At the end of Friday’s trade, Shares of AmerisourceBergen Corp. (NYSE:ABC), gained 0.06% to $103.94.
Asia Bio-Chem Group Corp., declared that Elaine Zhao has resigned as Chief Financial Officer (“CFO”) and director of the Company effective July 31, 2015.
The Company intends to initiate a search for a replacement CFO and until such time a new CFO is designated, Zhiping Wang, President and Chief Executive Officer of the Company, will serve as interim CFO effective July 31, 2015.
AmerisourceBergen Corporation sources and distributes pharmaceutical products to healthcare providers, pharmaceutical and biotech manufacturers, and specialty drug patients in the United States and internationally.
Finally, Starwood Hotels & Resorts Worldwide Inc (NYSE:HOT), ended its last trade with -0.51% loss, and closed at $75.39.
Starwood Hotels & Resorts Worldwide declared three more Element hotels set to open in Greater China in the next four years, following the recent opening of the Element brand’s Asia Pacific flagship Element Suzhou Science and Technology Town in Suzhou, China. With the increasing trend of guests seeking eco-conscious alternatives and a growing importance of sustainable development led by the Chinese government’s commitment to environmental protection, Element is well-positioned to meet growing demand with its sustainable programming and nature-inspired room offerings, designed to fuel a life of balance while on the road.
Starwood Hotels & Resorts Worldwide, Inc., together with its auxiliaries, operates as a hotel and leisure company worldwide. The company owns, operates, and franchises luxury and upscale full-service hotels, resorts, residences, retreats, select-service hotels, and extended stay hotels under the St. Regis,
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
